You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

COAGADEX Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Tradename: COAGADEX
High Confidence Patents:0
Applicants:1
BLAs:1
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for COAGADEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for COAGADEX Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for COAGADEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for COAGADEX

Introduction to COAGADEX

COAGADEX, developed by Bio Products Laboratory (BPL), is a groundbreaking biologic drug that has revolutionized the treatment of hereditary factor X deficiency. Approved by the FDA in 2015, it is the first and only specific factor X concentrate available in the U.S. market, marking a significant advancement in the management of this rare bleeding disorder[1][5].

Market Need and Patient Population

Hereditary factor X deficiency is a rare condition affecting approximately 300-600 patients in the U.S. These patients have inadequate amounts of circulating factor X, a crucial component of the coagulation system, and are at increased risk of bleeding. The lack of specific treatments prior to COAGADEX's approval meant patients were often managed with fresh-frozen plasma or plasma-derived prothrombin complex concentrates, which are less targeted and may introduce unnecessary clotting factors[1][5].

FDA Approval and Clinical Significance

The FDA approval of COAGADEX was a culmination of extensive clinical studies and input from renowned coagulation experts. The drug has been demonstrated to be effective in controlling bleeding episodes in patients with moderate to severe hereditary factor X deficiency. This approval has significantly expanded treatment options for patients with this rare disorder, providing a more targeted and efficient way to manage their condition[1][5].

Market Growth and Demand

The market for coagulation factor deficiency treatments, including COAGADEX, is experiencing robust growth. This expansion is driven by several factors:

  • Advancements in Biotechnology: Innovations in therapeutic options have improved patient outcomes and increased demand for specific coagulation factor products[3].
  • Increasing Prevalence of Bleeding Disorders: Rising awareness about bleeding disorders and the importance of early diagnosis and treatment have contributed to the growing demand for coagulation factor products[3].
  • Government Initiatives and Reimbursement Policies: Favorable government initiatives and reimbursement policies support the treatment of rare diseases, further boosting market growth[3].

Financial Performance of BPL

Bio Products Laboratory has seen significant financial growth, particularly driven by the success of COAGADEX along with other products like Gammaplex® and albumin products.

  • Record Sales: BPL reported record sales in the U.S. and double-digit growth in all three business regions (U.S., UK, and Intercontinental) in 2021. The U.S. market saw a 14% growth, while the UK and Intercontinental regions experienced 23% and 31% growth, respectively[2].
  • Strong Demand: The strong demand for COAGADEX, along with other products, contributed to a 15% year-on-year sales growth in BPL Therapeutics. This growth is part of a broader trend, with BPL achieving a 22% sales growth in FY 2020 and a 16% year-on-year sales growth in FY 2021[2].
  • Strategic Investments: BPL has invested in expanding its infrastructure, including the launch of a new Sterile Filling Suite at the Elstree site, which will support the increasing global demand for specialized plasma-derived medicinal products[2].

Global Expansion

BPL's success with COAGADEX is not limited to the U.S. market. The company is expanding its global presence:

  • China Market: BPL has been granted a license by the National Medical Products Administration (NMPA) to market its Albuminex® 25% product in China, which is the largest albumin market in the world. This move is part of BPL's strategy to grow its presence in key international markets[2].
  • Mexico and Other Regions: BPL has also made its first direct sale in Mexico and is planning to grow its presence in this market. The company's global strategy includes opening new plasma collection centers and expanding its distribution network[2].

Pharmacokinetics and Clinical Use

COAGADEX has been extensively studied for its pharmacokinetic properties. The drug's pharmacokinetics are characterized by a half-life of approximately 30.3 hours and a mean maximum concentration (Cmax) of 0.504 IU/mL following a single dose of 25 IU/kg. These parameters indicate that COAGADEX provides stable and effective factor X replacement, which is crucial for managing bleeding episodes in patients with hereditary factor X deficiency[4].

Industry Expert Insights

Industry experts highlight the significance of COAGADEX in the treatment landscape:

"The approval of Coagadex is a significant advancement for patients who suffer from this rare but serious disease," said Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research[5].

David Gao, BPL’s Vice Chairman & Chief Executive Officer, also emphasized the company's commitment to patient well-being and its strategic growth plans:

"In 2021, BPL has hit some key historic milestones in the US and is readying its launch of Albuminex in China. I want to thank our worldwide team for their focused delivery of our business targets and their commitment to the well-being of donors and patients we serve."[2]

Key Takeaways

  • Market Growth: The coagulation factor deficiency market is experiencing robust growth driven by advancements in biotechnology and increasing awareness of bleeding disorders.
  • Financial Performance: BPL has seen significant financial growth, with record sales and double-digit growth in all business regions, driven by strong demand for COAGADEX and other products.
  • Global Expansion: BPL is expanding its global presence, including new markets in China and Mexico, and investing in infrastructure to support growing demand.
  • Clinical Significance: COAGADEX is the first and only FDA-approved specific factor X concentrate, providing a targeted treatment for hereditary factor X deficiency.

FAQs

Q: What is COAGADEX and what is it used for? A: COAGADEX is a biologic drug used to treat hereditary factor X deficiency, a rare bleeding disorder. It is the first and only FDA-approved specific factor X concentrate.

Q: How does COAGADEX work? A: COAGADEX works by replacing the missing factor X in patients with hereditary factor X deficiency, helping to restore normal blood clotting.

Q: What are the key pharmacokinetic parameters of COAGADEX? A: COAGADEX has a half-life of approximately 30.3 hours and a mean maximum concentration (Cmax) of 0.504 IU/mL following a single dose of 25 IU/kg.

Q: How has the FDA approval of COAGADEX impacted the treatment landscape? A: The FDA approval of COAGADEX has significantly expanded treatment options for patients with hereditary factor X deficiency, providing a more targeted and efficient way to manage their condition.

Q: What are the financial implications of COAGADEX for BPL? A: COAGADEX has contributed to BPL's strong financial performance, including record sales and double-digit growth in all business regions, driven by strong demand for the product.

Sources

  1. Bio Products Laboratory Receives FDA Approval For Coagadex ... - BioSpace
  2. BPL Full Year 2021 Results: BPL delivers another strong performance - BPL Group
  3. Coagulation Factor Deficiency Market - US to Have the Lion's Share ... - PR Newswire
  4. Coagadex-USPI_14-Apr-2023.pdf - Coagadex
  5. FDA Approves Coagadex®, First Factor X Concentrate | NBDF - National Hemophilia Foundation
Last updated: 2024-12-18

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.